Home » Regions » Global News » Neurelis, Biotie Therapies partners, with acquisition option

Neurelis, Biotie Therapies partners, with acquisition option

Thursday, June 6, 2013

Pharmaceutical company Neurelis has signed an agreement with Biotie Therapies, a specialized drug development company, to develop intranasal diazepam (NRL-1) and provide Biotie with the exclusive option, but not the obligation, to acquire all outstanding shares of Neurelis.

Biotie will pay $1 million to Neurelis for the exclusive option to acquire all outstanding shares of Neurelis. During the option period, Biotie will conduct the development program for NRL-1 and work with Neurelis to advance the program with the FDA in preparation for the NDA submission. If the option is exercised and the merger consummated, Biotie will pay $8.75 million, subject to certain adjustments, in new ordinary shares of Biotie. Stockholders of Neurelis also will be eligible to receive additional milestone payments based on certain regulatory and commercial milestones.

NRL-1 is a proprietary formulation of diazepam delivered via a commercially available nasal sprayer.  It is being developed for patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity. 

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!